0 XP   0   0   0

Novo Nordisk A/S
Buy, Hold or Sell?

Should you buy, hold or sell Novo Nordisk A/S?

I guess you are interested in Novo Nordisk A/S. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Novo Nordisk A/S

Let's start. I'm going to help you getting a better view of Novo Nordisk A/S. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Novo Nordisk A/S even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Novo Nordisk A/S is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Novo Nordisk A/S. The closing price on 2023-02-03 was €125.98 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Novo Nordisk A/S Daily Candlestick Chart
Novo Nordisk A/S Daily Candlestick Chart
Summary









1. Valuation of Novo Nordisk A/S




Current price per share

€125.98

2. Growth of Novo Nordisk A/S




Is Novo Nordisk A/S growing?

Current yearPrevious yearGrowGrow %
How rich?$11.1b$9.5b$868.4m8.3%

How much money is Novo Nordisk A/S making?

Current yearPrevious yearGrowGrow %
Making money$1.9b$1.7b$157.5m8.2%
Net Profit Margin31.5%34.0%--

How much money comes from the company's main activities?

3. Financial Health of Novo Nordisk A/S




Comparing to competitors in the industry




  Industry Rankings ()  



Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

1.1. Profitability of Novo Nordisk A/S.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Novo Nordisk A/S earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Novo Nordisk A/S to the  industry mean.
  • A Net Profit Margin of 31.6% means that €0.32 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Novo Nordisk A/S:

  • The MRQ is 31.6%. The company is making a huge profit. +2
  • The TTM is 31.5%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ31.6%TTM31.5%+0.1%
TTM31.5%YOY34.0%-2.5%
TTM31.5%5Y32.0%-0.5%
5Y32.0%10Y32.0%0.0%
1.1.2. Return on Assets

Shows how efficient Novo Nordisk A/S is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Novo Nordisk A/S to the  industry mean.
  • 5.9% Return on Assets means that Novo Nordisk A/S generated €0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Novo Nordisk A/S:

  • The MRQ is 5.9%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 6.2%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ5.9%TTM6.2%-0.3%
TTM6.2%YOY7.0%-0.8%
TTM6.2%5Y6.4%-0.2%
5Y6.4%10Y6.4%0.0%
1.1.3. Return on Equity

Shows how efficient Novo Nordisk A/S is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Novo Nordisk A/S to the  industry mean.
  • 18.8% Return on Equity means Novo Nordisk A/S generated €0.19 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Novo Nordisk A/S:

  • The MRQ is 18.8%. Using its investors money, the company is efficient in making profit. +1
  • The TTM is 18.4%. Using its investors money, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ18.8%TTM18.4%+0.4%
TTM18.4%YOY18.3%+0.0%
TTM18.4%5Y18.4%+0.0%
5Y18.4%10Y18.4%0.0%

1.2. Operating Efficiency of Novo Nordisk A/S.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Novo Nordisk A/S is operating .

  • Measures how much profit Novo Nordisk A/S makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Novo Nordisk A/S to the  industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Novo Nordisk A/S:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
1.2.2. Operating Ratio

Measures how efficient Novo Nordisk A/S is keeping operating costs low.

  • Below 1 is considered healthy (always compare to  industry mean).
  • An Operation Ratio of 0.72 means that the operating costs are €0.72 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Novo Nordisk A/S:

  • The MRQ is 0.715. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.733. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.715TTM0.733-0.018
TTM0.733YOY0.742-0.009
TTM0.7335Y0.735-0.002
5Y0.73510Y0.7350.000

1.3. Liquidity of Novo Nordisk A/S.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Novo Nordisk A/S is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to  industry mean).
  • A Current Ratio of 0.92 means the company has €0.92 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Novo Nordisk A/S:

  • The MRQ is 0.917. The company is just not able to pay all its short-term debts. -1
  • The TTM is 0.905. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.917TTM0.905+0.012
TTM0.905YOY1.033-0.127
TTM0.9055Y0.931-0.025
5Y0.93110Y0.9310.000
1.3.2. Quick Ratio

Measures if Novo Nordisk A/S is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Novo Nordisk A/S to the  industry mean.
  • A Quick Ratio of 0.42 means the company can pay off €0.42 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Novo Nordisk A/S:

  • The MRQ is 0.419. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.448. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.419TTM0.448-0.029
TTM0.448YOY0.405+0.043
TTM0.4485Y0.440+0.009
5Y0.44010Y0.4400.000

1.4. Solvency of Novo Nordisk A/S.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Novo Nordisk A/S assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Novo Nordisk A/S to industry mean.
  • A Debt to Asset Ratio of 0.68 means that Novo Nordisk A/S assets are financed with 68.4% credit (debt) and the remaining percentage (100% - 68.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Novo Nordisk A/S:

  • The MRQ is 0.684. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.661. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.684TTM0.661+0.024
TTM0.661YOY0.620+0.040
TTM0.6615Y0.653+0.008
5Y0.65310Y0.6530.000
1.4.2. Debt to Equity Ratio

Measures if Novo Nordisk A/S is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Novo Nordisk A/S to the  industry mean.
  • A Debt to Equity ratio of 216.7% means that company has €2.17 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Novo Nordisk A/S:

  • The MRQ is 2.167. The company is just not able to pay all its debts with equity.
  • The TTM is 1.955. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ2.167TTM1.955+0.212
TTM1.955YOY1.633+0.322
TTM1.9555Y1.890+0.064
5Y1.89010Y1.8900.000

2. Market Valuation of Novo Nordisk A/S

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Novo Nordisk A/S generates.

  • Above 15 is considered overpriced but always compare Novo Nordisk A/S to the  industry mean.
  • A PE ratio of 118.54 means the investor is paying €118.54 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Novo Nordisk A/S:

  • The EOD is 147.190. Seems overpriced? -1
  • The MRQ is 118.542. Seems overpriced? -1
  • The TTM is 132.025. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD147.190MRQ118.542+28.648
MRQ118.542TTM132.025-13.483
TTM132.025YOY117.383+14.643
TTM132.0255Y129.097+2.929
5Y129.09710Y129.0970.000
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Novo Nordisk A/S.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Novo Nordisk A/S:

  • The MRQ is 109.320. Seems overpriced? -1
  • The TTM is 129.187. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ109.320TTM129.187-19.867
TTM129.1875Y129.1870.000
5Y129.18710Y129.1870.000

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Novo Nordisk A/S is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to industry mean).
  • A PB ratio of 22.27 means the investor is paying €22.27 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Novo Nordisk A/S:

  • The EOD is 27.651. Seems overpriced? -1
  • The MRQ is 22.269. Seems overpriced? -1
  • The TTM is 23.962. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD27.651MRQ22.269+5.382
MRQ22.269TTM23.962-1.693
TTM23.962YOY21.517+2.445
TTM23.9625Y23.473+0.489
5Y23.47310Y23.4730.000
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Novo Nordisk A/S compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.1440.170-16%3.876-96%0.911-84%0.911-84%
Book Value Growth--1.0301.040-1%--1.040-1%1.040-1%
Book Value Per Share--4.5564.252+7%3.876+18%4.176+9%4.176+9%
Book Value Per Share Growth--1.0331.043-1%--1.043-1%1.043-1%
Current Ratio--0.9170.905+1%1.033-11%0.931-1%0.931-1%
Debt To Asset Ratio--0.6840.661+4%0.620+10%0.653+5%0.653+5%
Debt To Equity Ratio--2.1671.955+11%1.633+33%1.890+15%1.890+15%
Dividend Per Share--0.5710.374+53%0.470+21%0.393+45%0.393+45%
Eps--0.8560.779+10%0.710+20%0.765+12%0.765+12%
Eps Growth--1.0841.060+2%--1.060+2%1.060+2%
Free Cash Flow Per Share--1.1890.858+39%1.162+2%0.919+29%0.919+29%
Free Cash Flow Per Share Growth--0.9381.953-52%--1.953-52%1.953-52%
Free Cash Flow To Equity Per Share--0.3240.271+19%0.474-32%0.312+4%0.312+4%
Free Cash Flow To Equity Per Share Growth--0.4992.498-80%--2.498-80%2.498-80%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--34.206--------
Intrinsic Value_10Y_min--29.642--------
Intrinsic Value_1Y_max--3.438--------
Intrinsic Value_1Y_min--3.377--------
Intrinsic Value_3Y_max--10.322--------
Intrinsic Value_3Y_min--9.854--------
Intrinsic Value_5Y_max--17.196--------
Intrinsic Value_5Y_min--15.962--------
Net Profit Margin--0.3160.315+0%0.340-7%0.320-1%0.320-1%
Operating Margin----0%-0%-0%-0%
Operating Ratio--0.7150.733-2%0.742-4%0.735-3%0.735-3%
Pb Ratio27.651+19%22.26923.962-7%21.517+3%23.473-5%23.473-5%
Pe Ratio147.190+19%118.542132.025-10%117.383+1%129.097-8%129.097-8%
Peg Ratio--109.320129.187-15%--129.187-15%129.187-15%
Price Per Share125.980+19%101.460101.6230%83.400+22%97.978+4%97.978+4%
Price To Total Gains Ratio176.263+19%141.956228.674-38%19.189+640%186.777-24%186.777-24%
Profit Growth--1.0821.056+2%--1.056+2%1.056+2%
Quick Ratio--0.4190.448-7%0.405+3%0.440-5%0.440-5%
Return On Assets--0.0590.062-4%0.070-15%0.064-7%0.064-7%
Return On Equity--0.1880.184+2%0.183+2%0.184+2%0.184+2%
Revenue Growth--1.1041.065+4%--1.065+4%1.065+4%
Total Gains Per Share--0.7150.544+31%4.346-84%1.305-45%1.305-45%
Total Gains Per Share Growth--1.4751.340+10%--1.340+10%1.340+10%
Usd Book Value--11108547252.00010446061772.300+6%9577572716.800+16%10272363961.200+8%10272363961.200+8%
Usd Book Value Change Per Share--0.1550.184-16%4.184-96%0.984-84%0.984-84%
Usd Book Value Per Share--4.9184.590+7%4.184+18%4.509+9%4.509+9%
Usd Dividend Per Share--0.6170.404+53%0.508+21%0.425+45%0.425+45%
Usd Eps--0.9240.841+10%0.767+20%0.826+12%0.826+12%
Usd Free Cash Flow--2899406164.6002096071896.875+38%2871156729.100+1%2251088863.320+29%2251088863.320+29%
Usd Free Cash Flow Per Share--1.2840.927+39%1.254+2%0.992+29%0.992+29%
Usd Free Cash Flow To Equity Per Share--0.3500.293+19%0.512-32%0.337+4%0.337+4%
Usd Price Per Share135.995+19%109.526109.7010%90.030+22%105.767+4%105.767+4%
Usd Profit--2086836504.5001913174910.625+9%1755666199.100+19%1881673168.320+11%1881673168.320+11%
Usd Revenue--6601096297.4006055338933.875+9%5160519955.800+28%5876375138.260+12%5876375138.260+12%
Usd Total Gains Per Share--0.7720.588+31%4.692-84%1.408-45%1.408-45%
 EOD+2 -3MRQTTM+28 -12YOY+17 -145Y+24 -1610Y+24 -16

3.2. Fundamental Score

Let's check the fundamental score of Novo Nordisk A/S based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15147.190
Price to Book Ratio (EOD)Between0-127.651
Net Profit Margin (MRQ)Greater than00.316
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.419
Current Ratio (MRQ)Greater than10.917
Debt to Asset Ratio (MRQ)Less than10.684
Debt to Equity Ratio (MRQ)Less than12.167
Return on Equity (MRQ)Greater than0.150.188
Return on Assets (MRQ)Greater than0.050.059
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Novo Nordisk A/S based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.474
Ma 20Greater thanMa 50126.920
Ma 50Greater thanMa 100124.918
Ma 100Greater thanMa 200116.264
OpenGreater thanClose121.680
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2022-09-30. Currency in DKK. All numbers in thousands.

Summary
Total Assets242,836,000
Total Liabilities166,156,000
Total Stockholder Equity76,680,000
 As reported
Total Liabilities 166,156,000
Total Stockholder Equity+ 76,680,000
Total Assets = 242,836,000

Assets

Total Assets242,836,000
Total Current Assets119,482,000
Long-term Assets119,482,000
Total Current Assets
Cash And Cash Equivalents 28,465,000
Short-term Investments 9,008,000
Net Receivables 45,563,000
Inventory 23,222,000
Total Current Assets  (as reported)119,482,000
Total Current Assets  (calculated)106,258,000
+/- 13,224,000
Long-term Assets
Long Term Investments 1,239,000
Long-term Assets  (as reported)123,354,000
Long-term Assets  (calculated)1,239,000
+/- 122,115,000

Liabilities & Shareholders' Equity

Total Current Liabilities130,257,000
Long-term Liabilities35,899,000
Total Stockholder Equity76,680,000
Total Current Liabilities
Short Long Term Debt 1,833,000
Accounts payable 8,310,000
Other Current Liabilities 27,972,000
Total Current Liabilities  (as reported)130,257,000
Total Current Liabilities  (calculated)38,115,000
+/- 92,142,000
Long-term Liabilities
Long term Debt 24,136,000
Long-term Liabilities Other 240,000
Long-term Liabilities  (as reported)35,899,000
Long-term Liabilities  (calculated)24,376,000
+/- 11,523,000
Total Stockholder Equity
Retained Earnings 73,673,000
Total Stockholder Equity (as reported)76,680,000
Total Stockholder Equity (calculated)73,673,000
+/- 3,007,000
Other
Capital Stock456,000
Common Stock Shares Outstanding 2,258,623
Net Invested Capital 102,649,000
Net Working Capital -10,775,000



Balance Sheet

Currency in DKK. All numbers in thousands.

 Trend2022-09-302022-06-302022-03-312021-12-312021-09-30
> Total Assets 
174,084,000
194,508,000
197,136,000
218,928,000
242,836,000
242,836,000218,928,000197,136,000194,508,000174,084,000
   > Total Current Assets 
91,213,000
85,595,000
86,537,000
102,979,000
119,482,000
119,482,000102,979,00086,537,00085,595,00091,213,000
       Cash And Cash Equivalents 
29,493,000
10,720,000
13,394,000
22,758,000
28,465,000
28,465,00022,758,00013,394,00010,720,00029,493,000
       Short-term Investments 
5,897,000
6,765,000
6,752,000
8,279,000
9,008,000
9,008,0008,279,0006,752,0006,765,0005,897,000
       Net Receivables 
29,860,000
40,643,000
36,241,000
40,826,000
45,563,000
45,563,00040,826,00036,241,00040,643,00029,860,000
       Inventory 
18,899,000
19,621,000
20,289,000
21,706,000
23,222,000
23,222,00021,706,00020,289,00019,621,00018,899,000
   > Long-term Assets 
82,871,000
108,913,000
110,599,000
115,949,000
123,354,000
123,354,000115,949,000110,599,000108,913,00082,871,000
       Goodwill 
0
4,346,000
0
0
0
0004,346,0000
       Long Term Investments 
1,778,000
1,441,000
1,279,000
1,242,000
1,239,000
1,239,0001,242,0001,279,0001,441,0001,778,000
       Intangible Assets 
0
38,825,000
0
0
0
00038,825,0000
> Total Liabilities 
107,972,000
123,762,000
130,586,000
144,476,000
166,156,000
166,156,000144,476,000130,586,000123,762,000107,972,000
   > Total Current Liabilities 
88,328,000
99,516,000
95,602,000
109,655,000
130,257,000
130,257,000109,655,00095,602,00099,516,00088,328,000
       Short Long Term Debt 
1,350,000
12,862,000
1,396,000
1,256,000
1,833,000
1,833,0001,256,0001,396,00012,862,0001,350,000
       Accounts payable 
8,877,000
8,870,000
6,679,000
14,654,000
8,310,000
8,310,00014,654,0006,679,0008,870,0008,877,000
       Other Current Liabilities 
19,239,000
21,784,000
24,117,000
24,014,000
27,972,000
27,972,00024,014,00024,117,00021,784,00019,239,000
   > Long-term Liabilities 
19,644,000
24,246,000
34,984,000
34,821,000
35,899,000
35,899,00034,821,00034,984,00024,246,00019,644,000
       Long term Debt 
12,398,000
9,654,000
24,084,000
24,178,000
24,136,000
24,136,00024,178,00024,084,0009,654,00012,398,000
       Capital Lease Obligations Min Short Term Debt
0
4,129,000
0
0
0
0004,129,0000
       Long-term Liabilities Other 
0
360,000
257,000
167,000
240,000
240,000167,000257,000360,0000
> Total Stockholder Equity
66,112,000
70,746,000
66,550,000
74,452,000
76,680,000
76,680,00074,452,00066,550,00070,746,00066,112,000
   Common Stock00000
   Retained Earnings 
67,914,000
72,004,000
66,612,000
73,166,000
73,673,000
73,673,00073,166,00066,612,00072,004,00067,914,000
   Capital Surplus 00000
   Treasury Stock00000
   Other Stockholders Equity 00000



Balance Sheet

Currency in DKK. All numbers in thousands.




Cash Flow

Currency in DKK. All numbers in thousands.




Income Statement

Currency in DKK. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue140,800,000
Cost of Revenue-23,658,000
Gross Profit117,142,000117,142,000
 
Operating Income (+$)
Gross Profit117,142,000
Operating Expense-82,156,000
Operating Income58,644,00034,986,000
 
Operating Expense (+$)
Research Development17,772,000
Selling General Administrative41,058,000
Selling And Marketing Expenses-
Operating Expense82,156,00058,830,000
 
Net Interest Income (+$)
Interest Income231,000
Interest Expense-289,000
Net Interest Income-180,000-58,000
 
Pretax Income (+$)
Operating Income58,644,000
Net Interest Income-180,000
Other Non-Operating Income Expenses-
Income Before Tax (EBT)59,080,00058,028,000
EBIT - interestExpense = -289,000
47,757,000
48,046,000
Interest Expense289,000
Earnings Before Interest and Taxes (ebit)-59,369,000
Earnings Before Interest and Taxes (ebitda)65,394,000
 
After tax Income (+$)
Income Before Tax59,080,000
Tax Provision-11,323,000
Net Income From Continuing Ops47,757,00047,757,000
Net Income47,757,000
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net616,000180,000
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
PFC.V
20 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of PFC.V.

PFC.V Daily Candlestick Chart
0IAH.LSE
20 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 0IAH.LSE.

0IAH.LSE Daily Candlestick Chart
VUAG.LSE
20 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VUAG.LSE.

VUAG.LSE Daily Candlestick Chart
0I5O.LSE
20 hours ago

I found you a MACD Bearish Reversal Divergence on the daily chart of 0I5O.LSE.

0I5O.LSE Daily Candlestick Chart
XDWE.LSE
20 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of XDWE.LSE.

XDWE.LSE Daily Candlestick Chart
XACT-BULL-2.ST
20 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of XACT-BULL-2.ST.

XACT-BULL-2.ST Daily Candlestick Chart
XACT-BULL.ST
20 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of XACT-BULL.ST.

XACT-BULL.ST Daily Candlestick Chart
XACT-BEAR.ST
20 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of XACT-BEAR.ST.

XACT-BEAR.ST Daily Candlestick Chart
WLDL.LSE
20 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of WLDL.LSE.

WLDL.LSE Daily Candlestick Chart
UNIBAP.ST
20 hours ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of UNIBAP.ST.

UNIBAP.ST Daily Candlestick Chart
S9I.XETRA
20 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of S9I.XETRA.

S9I.XETRA Daily Candlestick Chart
SGL.XETRA
20 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SGL.XETRA.

SGL.XETRA Daily Candlestick Chart
TEQ.ST
20 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of TEQ.ST.

TEQ.ST Daily Candlestick Chart
TDGB.LSE
20 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of TDGB.LSE.

TDGB.LSE Daily Candlestick Chart
SC04.XETRA
20 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SC04.XETRA.

SC04.XETRA Daily Candlestick Chart
SVIK.ST
20 hours ago

I found you a Bullish Engulfing Candle Pattern on the daily chart of SVIK.ST.

SVIK.ST Daily Candlestick Chart
PA8.XETRA
20 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of PA8.XETRA.

PA8.XETRA Daily Candlestick Chart
SPEP.LSE
20 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SPEP.LSE.

SPEP.LSE Daily Candlestick Chart
SP5L.LSE
20 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SP5L.LSE.

SP5L.LSE Daily Candlestick Chart
SLEEP.ST
20 hours ago

I found you a STOCH Bearish Hidden Divergence on the daily chart of SLEEP.ST.

SLEEP.ST Daily Candlestick Chart
SIVE.ST
20 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SIVE.ST.

SIVE.ST Daily Candlestick Chart
SGEA.LSE
20 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SGEA.LSE.

SGEA.LSE Daily Candlestick Chart
SECU-B.ST
20 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SECU-B.ST.

SECU-B.ST Daily Candlestick Chart
SBUY.LSE
20 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SBUY.LSE.

SBUY.LSE Daily Candlestick Chart